AZN logo

AZN

AstraZeneca PLC

$174.93
-$2.96(-1.66%)
41
Overall
50
Value
10
Tech
63
Quality
How is this score calculated?
Market Cap
$549.23B
Volume
1.67M
52W Range
$137.23 - $212.71
Target Price
$218.39

Company Overview

Mkt Cap$549.23BPrice$174.93
Volume1.67MChange-1.66%
P/E Ratio53.7Open$177.67
Revenue$58.7BPrev Close$177.89
Net Income$10.2B52W Range$137.23 - $212.71
Div Yield5.30%Target$218.39
Overall41Value50
Quality63Technical10

No chart data available

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Major

Latest News

AstraZeneca Advances Fixed-Dose Cholesterol Combo With New Phase I Bioavailability Data

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) is running a Phase I trial called “A Phase I Study...

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

Jefferies Remains a Buy on AstraZeneca (AZN)

TipRanks Auto-Generated Intelligence Newsdesk4 days ago

Citi Initiates a Buy Rating on AstraZeneca (AZN)

TipRanks Auto-Generated Intelligence Newsdesk5 days ago

AstraZeneca’s AZD1390 ADME Study Lays Groundwork for Future Oncology Upside

TipRanks Clinical-Trials-Auto-Generated Newsdesk8 days ago

AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test

TipRanks Clinical-Trials-Auto-Generated Newsdesk8 days ago
ABCD
1SymbolPriceChangeVol
2AZN$174.93-1.7%1.67M
3
4
5
6

Get AstraZeneca PLC Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.